Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Denali Therapeutics (NASDAQ: DNLI) announced topline results from Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 for amyotrophic lateral sclerosis (ALS) treatment. The study did not meet its primary endpoint of slowing disease progression compared to placebo, measured by ALS Functional Rating Scale-Revised (ALSFRS-R) and survival through week 24.